Zhu L, Feng H, Jia J D, Peng S, Li Y Q, Shao J F, He X F, Guan Y, Guo H, Lin Z B, Chen G
Key Laboratory of Organ Transplantation, Ministry of Public Health/Education, Institute of Organ Transplantation, Tongji Hospital, Huazhong University of Science and Technology, Wuhan 430030, China.
Zhonghua Yi Xue Za Zhi. 2018 Jan 16;98(3):176-180. doi: 10.3760/cma.j.issn.0376-2491.2018.03.004.
To investigate the therapeutic efficacy of tonsillectomy for patients with recurrence of IgA nephropathy (IgAN) after kidney transplantation. From May 2014, tonsillectomy was performed in 11 renal transplant patients with biopsy-proved recurrent IgAN. In a median follow-up of 14 (4-38) months, data of proteinuria, hematuria, estimated glomerular filtration rate (eGFR), and serum levels of IgA in these patients were compared before and after tonsillectomy.Patient's survival and renal graft survival were also summarized. A remission of proteinuria was observed in 8 patients after tonsillectomy, and this status maintained well in the subsequent follow-up.Three patients had no or minimal reduction of proteinuria after tonsillectomy and returned to dialysis within 1 year after tonsillectomy.Possible causes could be severe primary IgAN of crescentric glomerulonephritis, IgAN recurrence in kidney retransplantation, and late tonsillectomy after IgAN recurrence.Serum levels of IgA significant decreased and no patients developed acute rejection or infection after tonsillectomy.In the 1-year follow-up, no patients died and grafts survived well in 8 out of 11 patients. Tonsillectomy may represent an effective and reliable way to treat recurrence IgAN after kidney transplantation, and may be applied widely in the future clinical management. However, early intervention is critical and effects may depend on the pathological features of primary IgAN.
探讨扁桃体切除术对肾移植后IgA肾病(IgAN)复发患者的治疗效果。自2014年5月起,对11例经活检证实为复发性IgAN的肾移植患者实施了扁桃体切除术。在中位随访14(4 - 38)个月期间,比较了这些患者扁桃体切除术前、后的蛋白尿、血尿、估计肾小球滤过率(eGFR)及血清IgA水平数据。还总结了患者生存率和肾移植存活率。扁桃体切除术后8例患者蛋白尿缓解,且在后续随访中维持良好。3例患者扁桃体切除术后蛋白尿无减少或减少甚微,并在扁桃体切除术后1年内恢复透析。可能的原因包括新月体性肾小球肾炎的严重原发性IgAN、肾再次移植时IgAN复发以及IgAN复发后扁桃体切除延迟。扁桃体切除术后血清IgA水平显著下降,且无患者发生急性排斥反应或感染。在1年的随访中,无患者死亡,11例患者中有8例移植肾存活良好。扁桃体切除术可能是治疗肾移植后复发性IgAN的一种有效且可靠的方法,未来可能会在临床管理中广泛应用。然而,早期干预至关重要,效果可能取决于原发性IgAN的病理特征。